News | Radiation Therapy | September 11, 2019

Beta Testing begins of RadCalc 3Dmc version 7.1.1.0 utilizing Monte Carlo 3D dose volume QA technology

RadCalc 3D Monte Carlo Calculations for Photons Begins Beta Testing

September 11, 2019 — RadCalc version 7.1 with the Monte Carlo 3-D module has been released for beta testing to members of the beta testing team. The Monte Carlo 3D module utilizes technology acquired from the McGill University inventors. This release of RadCalc 3Dmc is the second of three 3D Dose Volume second check quality assurance (QA) packages. The completion of the beta test is anticipated in four weeks. An announcement of the final release date will be provided when available for purchase.

RadCalc 3Dmc utilizes the BeamNRC-based Monte Carlo dose calculation engine, providing independent, fast, easy and accurate 3-D dose volume verification for most commonly used treatment planning systems. The RadCalc 3Dmc beta release is compatible with Varian and Elekta machines. Support for additional radiotherapy treatment machines will be available in the near future.

Monte Carlo is widely recognized as the gold standard dose calculation method. The most challenging clinical cases involving highly heterogeneous structures are analyzed with the highest accuracy and confidence. Flexible implementation options allow users to combine the uncompromised accuracy of a Monte Carlo dose calculation algorithm with the levels of speed and productivity that allow busy radiation departments to meet their workflow needs.

RadCalc 3Dmc includes RadCalc AIR (Automated Import & Report) providing a fully automated process with percent difference, dose volume histogram (DVH), Gamma, and Distance to Agreement analysis tools. RadCalc 3Dmc’s fully automated process immediately alerts users to plans that fail to pass pre-set criteria.

RadCalc 3Dmc automatically checks whether DVH objectives are met for critical structures using both the treatment planning system (TPS) and RadCalc 3Dmc dose. Any number of DVH protocols can be loaded and be compared to one another from one analysis screen within RadCalc 3Dmc. Analysis reports are automatically attached to a verified plan and sent to a workstation via email or to a directory of choice on the server.

RadCalc 3Dmc is not yet available for sale in the United States. 

For more information: www.lap-laser.com

Related Content

News | Breast Imaging

August 19, 2022 — The Christ Hospital Health Network, known for providing the best, most compassionate care for its ...

Time August 19, 2022
arrow
News | Proton Therapy

August 19, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the ...

Time August 19, 2022
arrow
News | Radiation Therapy

August 19, 2022 — Recently published research out of VCU Massey Cancer Center demonstrated that cancer patients who live ...

Time August 19, 2022
arrow
News | Prostate Cancer

August 16, 2022 — A new study published by University of Kentucky Markey Cancer Center researchers suggests that the ...

Time August 16, 2022
arrow
News | Breast Imaging

August 15, 2022 — Brainlab announced the first group of breast cancer patients treated in United States with the ...

Time August 15, 2022
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Did you know that Imaging Technology News (ITN) maintains more than 40 comparison charts of product specifications from ...

Time August 12, 2022
arrow
News | ASTRO

August 12, 2022 — The American Society for Radiation Oncology (ASTRO) today expressed its support for President Joseph R ...

Time August 12, 2022
arrow
News | Lung Imaging

August 10, 2022 — Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 ...

Time August 10, 2022
arrow
News | Prostate Cancer

August 9, 2022 — Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD ...

Time August 09, 2022
arrow
News | Breast Imaging

August 8, 2022 — The U.S. Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV ...

Time August 08, 2022
arrow
Subscribe Now